Showing 3411-3420 of 7760 results for "".
- It's Time to Celebrate Allergan Aesthetics' Fourth Annual BOTOX Cosmetic Dayhttps://practicaldermatology.com/news/its-time-to-celebrate-allergan-aesthetics-fourth-annual-botox-cosmetic-day/2461413/Allergan Aesthetics is inviting people across the country to take a "Moment for You" on Wednesday, November 16 and celebrate the biggest event of the year for Botox Cosmetic. For this year's celebration, BOTOX® Cosmetic is sharing two exclusive offers availab
- November is Hyperhidrosis Awareness Monthhttps://practicaldermatology.com/news/november-is-hyperhidrosis-awareness-month-1/2461411/November is Hyperhidrosis Awareness Month and the
- Monkeypox Update: Kids Aged 8 or Younger at High Risk for More Severe Monkeypoxhttps://practicaldermatology.com/news/monkey-pox-update-kids-aged-8-or-younger-at-high-risk-for-more-severe-monkeypox/2461409/Children aged 8 years or younger are at high risk for more severe monkeypox disease, reports The Pediatric Infectious Disease Journal. Young children would be a key target group for smallpox vaccination and other urgent measures if the outbreak widens, according to the review b
- EMA Accepts Filing of MAA for Almirall's Lebrikizumab in ADhttps://practicaldermatology.com/news/ema-accepts-filing-of-maa-for-almiralls-lebrikizumab-in-ad/2461408/The European Medicines Agency (EMA) has accepted the filing of the Marketing Authorization Application (MAA) for Almirall’s lebrikizumab for the treatment of moderate to severe atopic dermatitis. Lebrikizumab is a novel, investigational, monoclonal antibod
- Almirall’s New Psoriasis Campaign Sheds Light on How the Disease Affects Mental Health and Wellbeinghttps://practicaldermatology.com/news/almiralls-new-psoriasis-campaign-sheds-light-on-how-the-disease-affects-mental-health-and-wellbeing/2461407/Almirall and the International Federation of Psoriasis Association are launching the second edition of the "Shedding Light on Psoriasis" campaign for World Psoriasis Day 2022. Shedding Light on Psoriasis 
- Kintor Pharma Completes Enrollment and Dosing in Phase I Clinical Trial of AGA, Acne Drughttps://practicaldermatology.com/news/kintor-pharma-completes-enrollment-and-dosing-in-phase-i-clinical-trial-of-aga-acne-drug/2461404/Kintor Pharmaceutical Limited has completed the enrollment and dosing of 120 subjects for its U.S. phase I clinical trial of GT20029 for the treatment of androgenetic alopecia (AGA) and acne. Developed through Kintor Pharma's proprietary Proteolysis Targeting Chimera (PROTAC) platfo
- New Aveeno Report Reveals 71% of Adults Have Sensitive Skinhttps://practicaldermatology.com/news/new-aveeno-report-reveals-71-of-adults-have-sensitive-skin/2461401/The Aveeno brand has launched its first-ever State of Skin Sensitivity Report, which examines the causes of sensitive skin, and explores the connection between body, mind, and skin. While body positivity
- One Year Data: Cutera’s AviClear Continues to Improve Acnehttps://practicaldermatology.com/news/one-year-data-cuteras-aviclear-comtinues-to-improves-acne/2461400/Cutera, Inc.’s AviClear improves acne in 92 percent of patients at one year, according to research presented at the Annual Fall Clinical Dermatology Conference in Las Vegas. Current clinical studies show that after three 30-minute treatment sessions, 90 percent of patients had a v
- Nivolumab Shows Promise in Advanced SCChttps://practicaldermatology.com/news/nivolumab-shows-promise-in-advanced-scc/2461399/Numerous studies have shown that immune checkpoint inhibitors can boost the immune system’s response against various cancers, and now, a phase II clinical trial has demonstrated that patients with advanced cutaneous squamous cell carcinoma can benefit from nivolumab. The research is publish
- Hair Straightening Chemicals Associated with Higher Uterine Cancer Riskhttps://practicaldermatology.com/news/hair-straightening-chemicals-associated-with-higher-uterine-cancer-risk/2461397/Chemical hair straighteners may be contributing to a rise in aggressive uterine cancers a new study in the Journal of the National Cancer Institute suggests. The